- Home
- AFRI vs CGEN Comparison
AFRI vs CGEN Comparison
Compare AFRI & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFRI | CGEN |
|---|---|---|
| Founded | 1943 | 1993 |
| Country | Gibraltar | Israel |
| Employees | 600 | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.2M | 270.4M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | AFRI | CGEN |
|---|---|---|
| Price | $10.00 | $2.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 19.3K | ★ 551.5K |
| Earning Date | 05-12-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.47 | $1.30 |
| 52 Week High | $11.42 | $3.24 |
Technical Indicators
Market Signals| Indicator | AFRI | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 49.48 |
| Support Level | $9.87 | $2.54 |
| Resistance Level | $10.00 | $3.14 |
| Average True Range (ATR) | 0.20 | 0.18 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 28.32 | 34.95 |
Price Performance
Historical ComparisonAbout AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.